 Eyenovia, Inc. EYEN, a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print MAPTM therapeutics, today announced that the Company has resumed patient enrollment for its Phase III CHAPERONE study for the treatment of progressive myopia, following a temporary pause due to the COVID-19 pandemic. The study is investigating the safety and efficacy of MicroPine for the reduction of progressive myopia using Eyenovias proprietary atropine topical micro-formulation delivered by the OptejetTM dispenser. 